A Phase 3, Randomized, Double Blind, Adaptive, Placebo/Paclitaxel Controlled Study of AVB S6 500 in Combination With Paclitaxel in Patients With Platinum Resistant Recurrent Ovarian Cancer
For more information about the trial above please contact the study team:
Principal Investigator, Whitney Graybill, at email@example.com.
Study Coordinator, Linda Washington, at firstname.lastname@example.org.
Trial opened at the following institutions: Medical University of South Carolina